{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:32:47Z","timestamp":1793331167831,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.antiviral.2007.11.002","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T14:18:19Z","timestamp":1196777899000},"page":"125-131","source":"Crossref","is-referenced-by-count":128,"title":["Treatment of Crimean-Congo hemorrhagic fever"],"prefix":"10.1016","volume":"78","author":[{"given":"Onder","family":"Ergonul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2007.11.002_bib1","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1128\/JVI.78.8.4323-4329.2004","article-title":"Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus","volume":"78","author":"Andersson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jmv.20530","article-title":"Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells","volume":"78","author":"Andersson","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1099\/jmm.0.46910-0","article-title":"Haemophagocytosis in a patient with Crimean-Congo haemorrhagic fever","volume":"56","author":"Cagatay","year":"2007","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib4","unstructured":"Centers for Disease Control and Prevention, 2005. Bioterrorism http:\/\/wwwbtcdcgov\/Agent\/Agentlistasp."},{"key":"10.1016\/j.antiviral.2007.11.002_bib5","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1086\/521244","article-title":"Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever","volume":"45","author":"Cevik","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib6","first-page":"452","article-title":"Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions","volume":"29","author":"Cooper","year":"2003","journal-title":"Ped. Nurs."},{"key":"10.1016\/j.antiviral.2007.11.002_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","article-title":"Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma","volume":"2","author":"Enria","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2007.11.002_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1473-3099(06)70435-2","article-title":"Crimean-Congo haemorrhagic fever","volume":"6","author":"Ergonul","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib9","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"207","article-title":"Clinical and pathologic features of Crimean Congo hemorrhagic fever","author":"Ergonul","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib10","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"245","article-title":"Treatment of Crimean Congo hemorrhagic fever","author":"Ergonul","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib11","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"3","article-title":"Introduction","author":"Ergonul","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1086\/422000","article-title":"Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy","volume":"39","author":"Ergonul","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-0691.2006.01445.x","article-title":"Analysis of risk factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited","volume":"12","author":"Ergonul","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2007.11.002_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1086\/500836","article-title":"Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever","volume":"193","author":"Ergonul","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib15","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.1074\/jbc.M209628200","article-title":"ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses","volume":"278","author":"Espert","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2007.11.002_bib16","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/sj.onc.1207586","article-title":"The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation","volume":"23","author":"Espert","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2007.11.002_bib17","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1099\/vir.0.81074-0","article-title":"Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1","volume":"86","author":"Espert","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib18","article-title":"Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome","author":"Fisgin","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(95)91323-8","article-title":"Crimean Congo-haemorrhagic fever treated with oral ribavirin","volume":"346","author":"Fisher-Hoch","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2007.11.002_bib20","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"295","article-title":"International surveillance and control of Crimean-Congo hemorrhagic fever outbreaks","author":"Formenty","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/JVI.70.2.915-923.1996","article-title":"Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein","volume":"70","author":"Frese","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4269\/ajtmh.2007.77.514","article-title":"Development of a TaqMan minor groove binding protein assay for the detection and quantification of Crimean-Congo hemorrhagic fever virus","volume":"77","author":"Garrison","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2007.11.002_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib24","series-title":"Goodman and Gilman's: The Pharmacological Basis of Therapeutics","first-page":"1265","article-title":"Antiviral agents","author":"Hayden","year":"2006"},{"key":"10.1016\/j.antiviral.2007.11.002_bib25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI115217","article-title":"Inhibition of immune functions by antiviral drugs","volume":"87","author":"Heagy","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2007.11.002_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jmedent\/15.4.307","article-title":"The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa","volume":"15","author":"Hoogstraal","year":"1979","journal-title":"J. Med. Entomol."},{"key":"10.1016\/j.antiviral.2007.11.002_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/0019-5359.26609","article-title":"Crimean-Congo hemorrhagic fever: case series from a medical center in Golestan province, Northeast of Iran (2004)","volume":"60","author":"Jabbari","year":"2006","journal-title":"Indian J. Med. Sci."},{"key":"10.1016\/j.antiviral.2007.11.002_bib29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3201\/eid1008.030928","article-title":"Crimean-Congo hemorrhagic fever in Turkey","volume":"10","author":"Karti","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib30","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.052430399","article-title":"Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes","volume":"99","author":"Kochs","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2007.11.002_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2008.01.004","article-title":"Molecular targets for new drugs against highly pathogenic RNA viruses","volume":"78","author":"Leyssen","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2007.11.002_bib32","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2007.11.002_bib33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1086\/375058","article-title":"The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran","volume":"36","author":"Mardani","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib34","series-title":"Manual of Clinical Hematology","author":"Mazza","year":"2002"},{"key":"10.1016\/j.antiviral.2007.11.002_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever: effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2007.11.002_bib36","series-title":"Reports of the Communicable Diseases Department","author":"Ministry of Health","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib37","series-title":"Crimean-Congo Hemorrhagic Fever: A Global Perspective","first-page":"258","article-title":"Old and new treatment strategies","author":"Mirazimi","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib38","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"155","article-title":"Crimean-Congo hemorrhagic fever virus infection among animals","author":"Nalca","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2005.05.003","article-title":"Crimean-Congo hemorrhagic fever in eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy","volume":"52","author":"Ozkurt","year":"2006","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2007.11.002_bib40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3201\/eid0808.010448","article-title":"Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia","volume":"8","author":"Papa","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2003.11.006","article-title":"A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus","volume":"62","author":"Paragas","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2007.11.002_bib42","series-title":"Blood Banking and Transfusion Medicine","first-page":"181","article-title":"Platelets and related products","author":"Perrota","year":"2003"},{"key":"10.1016\/j.antiviral.2007.11.002_bib43","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1600-0854.2004.00219.x","article-title":"Missorting of La Crosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves smooth ER membranes","volume":"5","author":"Reichelt","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.antiviral.2007.11.002_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":"Viruses of the Bunya and Togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003","journal-title":"Antiviral Res."},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2007.11.002_bib45","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1093\/clinids\/11.Supplement_4.S794","article-title":"The clinical pathology of Crimean-Congo hemorrhagic fever","volume":"11","author":"Swanepoel","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.antiviral.2007.11.002_bib46","series-title":"Crimean-Congo Hemorrhagic Fever: A Global Perspective","first-page":"281","article-title":"Estimates and prevention of Crimean Congo hemorrhagic fever risks for health care workers","author":"Tarantola","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-3542(93)90040-P","article-title":"Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection","volume":"22","author":"Tignor","year":"1993","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2007.11.002_bib48","first-page":"718","article-title":"A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital. Part II. Management of patients","volume":"68","author":"Van Eeden","year":"1985","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.antiviral.2007.11.002_bib49","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(04)16261-2","article-title":"When are observational studies as credible as randomised trials?","volume":"363","author":"Vandenbroucke","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2007.11.002_bib50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0140-6736(90)90906-L","article-title":"Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever","volume":"335","author":"Vassilenko","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2007.11.002_bib51","series-title":"Crimean Congo Hemorrhagic Fever: A Global Perspective","first-page":"59","article-title":"Crimean-Congo hemorrhagic fever in Turkey","author":"Vatansever","year":"2007"},{"key":"10.1016\/j.antiviral.2007.11.002_bib52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4269\/ajtmh.1989.41.581","article-title":"Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin","volume":"41","author":"Watts","year":"1989","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2007.11.002_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.antiviral.2004.08.001","article-title":"Crimean-Congo hemorrhagic fever","volume":"64","author":"Whitehouse","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2007.11.002_bib54","series-title":"Crimean-Congo Hemorrhagic Fever: A Global Perspective","first-page":"273","article-title":"Risk groups and control measures for Crimean Congo hemorrhagic fever","author":"Whitehouse","year":"2007"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354207004688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354207004688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T03:54:36Z","timestamp":1588132476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354207004688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0166354207004688"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2007.11.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}